Humanwell Healthcare Receives NMPA Approval for Chemically Synthesized Semaglutide Clinical Trial
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079), a leading healthcare company based in China, has...
Diabetes
Eccogene Inc. Secures $60 Million Milestone Payment from AstraZeneca for ECC5004/AZD5004
Sino-US firm Eccogene Inc. announced on October 23rd that it is set to receive a...
Huahai Pharmaceutical Gets FDA Nod for Generic Empagliflozin and Metformin ANDA
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a prominent Chinese pharmaceutical company, has announced the...
Lexicon Pharmaceuticals Strikes Licensing Deal with Viatris for Global Expansion of Sotagliflozin
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has entered into a licensing agreement with Viatris Inc. (NASDAQ:...
Lepu Medical Receives Approval for Noninvasive Blood Glucose Meter NeoGlu 01 in China
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...
Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders
Novo Nordisk (NYSE: NVO) has escalated its legal battles in the healthcare sector by filing...
Huadong Medicine Secures NMPA Approval for Semaglutide Biosimilar, Aims to Capture Weight Loss Market
Nanjing-based Huadong Medicine Co., Ltd (SHE: 000963) has received clinical trial approval from China’s National...
Eli Lilly & Co. Boosts Suzhou Plant with $211M to Meet Diabetes and Obesity Drug Demand
Eli Lilly & Co.(NYSE: LLY)’s China subsidiary is poised to invest a substantial RMB 1.5...
Kailera Therapeutics Emerges with USD 400 Million in Series A Funding for Anti-Obesity Pipeline
Kailera Therapeutics, a newly launched US-based biotechnology company, secured USD 400 million in Series A...
LenoMed Medical’s Touch-Insulin Pump Receives NMPA Approval, Aids China’s Diabetes Management
Shanghai-based LenoMed Medical, a medical device platform company backed by Legend Capital and Legend Star,...
ClouDr Receives NMPA Green Light for ClouDT-01, a Groundbreaking Digital Diabetes Treatment
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the banner of “ClouDr” on the...
Huadong Medicine Secures Exclusive Rights to Janagliflozin for Type 2 Diabetes Treatment in China
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing...
Innovent Biologics’ Mazdutide Outperforms Dulaglutide in Phase III T2D Study at EASD Meeting
Innovent Biologics, Inc. (HKG: 1801), a biopharmaceutical company based in China, has presented significant findings...
Manufacturing Challenges for Novo Nordisk’s Ozempic Impact Diabetes and Obesity Treatments in Europe
Novo Nordisk (NYSE: NVO), a leading Danish pharmaceutical company, has released a joint statement with...
Novo Nordisk to Resubmit Wegovy Heart Failure Application with Updated Clinical Data
Denmark’s pharmaceutical giant, Novo Nordisk (NYSE: NVO), has reported significant findings on the efficacy of...
Jiyuan Biotechnology’s Stem Cell Therapy for Type 2 Diabetes Gains NMPA Tacit Approval for Clinical Trials
BEIJING—Jiyuan Biotechnology, a leading Chinese biopharmaceutical company, has secured tacit clinical trial approval from the...
SynthAsia and Shanghai General Hospital Partner to Advance Diabetic Retinopathy Research
SynthAsia has forged a strategic partnership with Shanghai General Hospital, focusing on scientific innovation within...
Eli Lilly Unveils $700 Million R&D Center in Boston to Boost Genetic Medicine Efforts
Eli Lilly & Co. (NYSE: LLY) has inaugurated its new R&D center in Boston’s Seaport...
Sihuan Pharmaceutical Secures NMPA Approval for First Biosimilars of Novo Nordisk’s Diabetes Drugs
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has secured separate marketing approvals from China’s National...
JiAnTeBo and Sanyou Biopharmaceuticals Join Forces to Discover Metabolic Disease Targets and Develop Agonistic Antibodies
Guangdong JiAnTeBo Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a strategic partnership...